FDLI is pleased to invite members to participate in a virtual “Author Happy Hour” to discuss the article, “Taking Stock of PFDD: Envisioning a Vibrant Future for Patient-Focused Drug Development,” published in the Spring 2020 issue of Update magazine. Join two authors from the PFDDworks collaborative forum, Annie Kennedy and David Zook, and your peers in the food and drug law community in this video call to discuss the impacts of the PFDD initiative and recommendations for the future. Be prepared to ask the authors questions and engage in a dialogue on these and other topics presented in the article, all while enjoying your favorite beverage. This member-only benefit will be limited to twenty attendees to encourage participation and active discourse in a virtual setting.
Authors and Article
Annie Kennedy, Chief of Policy and Advocacy, EveryLife Foundation for Rare Diseases
David Zook, Chair, Faegre Drinker Consulting
June 18, 2020
5:00 PM EDT
Registration is open to FDLI members only and is first come, first served. Tickets are limited to 20 participants to facilitate conversation.
This is a complimentary event.
Questions About FDLI Membership?
Contact our membership team at [email protected].
For other questions, please contact Paige Samson.
ANNIE KENNEDY is Chief of Policy and Advocacy at EveryLife Foundation for Rare Diseases. Focused on improving health outcomes for people living with rare diseases by advancing the development of treatment and diagnostic opportunities for rare disease patients through science-driven public policy, Annie’s work includes building strong partnerships with policy makers, federal agencies, Industry, and alliances. Current areas of emphasis include leading the national Burden of Rare Disease Study, 21st Century Cures Act and PDUFA VII engagement, national newborn screening program engagement and state RUSP alignment legislation, and innovating around therapy valuation and access issues. 
DAVID ZOOK leads the Faegre Drinker LLP government and regulatory affairs group comprised of nearly 100 lawyers and consultants serving clients at the federal and state levels. His practice focuses on public policy matters in health, life sciences, and higher education. This work has included a number of landmark initiatives with patient advocacy clients across the biomedical research, public health, regulatory, and access domains. In the Patient-Focused Drug Development arena specifically, Dave and his colleagues have supported related provisions in FDARA and the 21st Century Cures Act, regulatory advocacy on PFDD guidances, planning and execution of externally-led PFDD meetings, disease community preparation of draft drug development guidance, and creation of patient experience data platforms.
